Literature DB >> 2149339

The interaction of clozapine with dopamine D1 versus dopamine D2 receptor-mediated function: behavioural indices.

A M Murray1, J L Waddington.   

Abstract

Studies were undertaken to clarify further the mechanism(s) of action of the atypical neuroleptic clozapine, using a behavioural model with the ability to distinguish between relative antagonism of D1 vs. D2 dopamine receptor-mediated function. Pretreatment with low doses of clozapine (2.5-25.0 mg/kg) readily antagonised intense grooming induced by the selective D1 agonist SK&F 77434 (0.75 mg/kg), and in a less consistent manner antagonised hyperactivities induced by the selective D2 agonist LY 163502 (0.05 mg/kg). In animals whose typical responses to SK&F 77434 were antagonised by clozapine, no atypical behaviours such as vacuous chewing emerged. However, in animals whose typical responses to LY 163502 were antagonised by clozapine, a syndrome of atypical limb/body jerking was released. Despite clozapine showing comparable affinities for D1 and D2 receptors in vitro, this behavioural profile shows similarities to that seen when these agonists are given after pretreatment with a selective D1 antagonist, rather than with a selective D2 antagonist or with non-selective neuroleptics. These results suggest that clozapine has some preferential though not selective action in vivo to antagonise D1 dopamine receptor-mediated function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2149339     DOI: 10.1016/0014-2999(90)94062-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  SDZ PSD 958, a novel D1 receptor antagonist with potential limbic selectivity.

Authors:  R Markstein; P Gull; C Rüdeberg; S Urwyler; A L Jaton; K McAllister; A K Dixon; D Hoyer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice.

Authors:  Andrew Nathanael Shen; M Christopher Newland
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

Review 3.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

4.  Effects of kappa receptor agonists on D1 and D2 dopamine agonist and antagonist-induced behaviors.

Authors:  C Marin; T M Engber; P Chaudhuri; A Peppe; T N Chase
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

5.  Dopamine uptake inhibition is positively correlated with cocaine-induced stereotyped behavior.

Authors:  Evgeny A Budygin
Journal:  Neurosci Lett       Date:  2007-10-11       Impact factor: 3.046

6.  Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213.

Authors:  A M Deveney; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

7.  Muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.

Authors:  R Rivest; C A Marsden
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

8.  The receptor mechanisms underlying the disruptive effects of haloperidol and clozapine on rat maternal behavior: a double dissociation between dopamine D(2) and 5-HT(2A/2C) receptors.

Authors:  Changjiu Zhao; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2009-06-17       Impact factor: 3.533

9.  The effects of clozapine on behavioural responses to the selective 'D1-like' dopamine receptor agonist, A 68930, and to the selective 'D2-like' agonist, RU 24213.

Authors:  S A Daly; J L Waddington
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

Review 10.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.